Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Neoadjuvant anlotinib for locally advanced thyroid cancer: a single-arm phase II study (ALTER-T001).

Created on 17 Nov 2026

Authors

Dapeng Li, Ankui Yang, Zhaohui Wang, Minghua Ge, Xiangqian Zheng, Songfeng Wei, Jianwu Qin, Shengying Wang, Youben Fan, Shuwei Chen, Yibo Chen, Naisi Huang, Zhuo Tan, Bin Zhou, Shoujun Wang, Yu Wang, Ming Gao

Published in

Frontiers in endocrinology. Volume 17. Pages 1960030. Epub Nov 02, 2026.

Abstract

Locally advanced thyroid cancer involving critical cervical structures is often not amenable to upfront surgery, and effective strategies are needed to improve surgical feasibility. ALTER-T001 study evaluated the safety, efficacy, and quality of life (QoL) of neoadjuvant anlotinib in this setting.
Patients with pathologically confirmed, locally advanced thyroid cancer not amenable to surgery received neoadjuvant anlotinib. "Not amenable to surgery" tumors included those unresectable, high-risk for surgery/recurrence, severely impairing QoL upon resection, or with limited adhesion to blood vessels, esophagus, or trachea. Primary endpoint was objective response rate (ORR). Secondary endpoints included time to response (TTR), disease control rate (DCR), actual operation rate, R0 resection rate, progression-free survival (PFS), QoL, and safety.
In 50 DTC patients, ORR and DCR were 42.0% and 84.0% (48.8% and 97.7% in 43 evaluable cases). Median TTR was 2.8 months. Surgery occurred in 21 (42.0%) patients, yielding a 57.1% R0 rate. Median PFS in non-surgical patients was 29.8 months. The most frequent grade ≥3 treatment-related adverse event (TRAE) was hypertension (18.0%). TRAEs led to dose reductions and interruptions in 8 (16.0%) and 5 (10.0%) patients, respectively. No treatment-related deaths occurred. Global health status remained generally stable during early treatment, although deterioration in several function domains was observed. One MTC patient achieved R0 resection after 4 cycles and is presented separately as a descriptive case.
Neoadjuvant anlotinib exhibited acceptable efficacy, tolerability, and QoL profiles in locally advanced DTC not amenable to surgery, with potential to reduce tumor burden and facilitate conversion surgery. Larger MTC cohorts are needed to further evaluate the efficacy and safety of neoadjuvant anlotinib.Clinical Trial Registration: https://www.chictr.org.cn/, identifier ChiCTR2100048077.

PMID:
43041253
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement